Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Finke

Showing results (231-240 of 270) with videos related to

Pageof 27
Sort By:
Bone Marrow Transplantation|December 8, 2015
Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?M C Oliveira, M Labopin, J Henes, et al.
Leukemia|August 13, 2010
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registryM Michallet, M Sobh, D Milligan, et al.
Bone Marrow Transplantation|August 6, 2003
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)A R Zander, N Kröger, M Schleuning, et al.
Bone Marrow Transplantation|February 9, 2016
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomasF Heinzelmann, W Bethge, D W Beelen, et al.
Bone Marrow Transplantation|June 2, 2016
Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?M C Oliveira, M Labopin, J Henes, et al.
ESMO Open|September 6, 2024
High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMTS Secondino, M Badoglio, G Rosti, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationS K Metzelder, T Schroeder, M Lübbert, et al.
Leukemia|June 1, 2017
High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study groupB Kasenda, G Ihorst, R Schroers, et al.
Bone Marrow Transplantation|December 1, 2015
Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working PartyS P Robinson, A Boumendil, H Finel, et al.
Bone Marrow Transplantation|November 2, 2004
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosisR Saccardi, A Tyndall, G Coghlan, et al.
Pageof 27

Showing results (231-240 of 270) with videos related to

Sort By:
Pageof 27
Bone Marrow Transplantation|December 8, 2015
Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?M C Oliveira, M Labopin, J Henes, et al.
Leukemia|August 13, 2010
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registryM Michallet, M Sobh, D Milligan, et al.
Bone Marrow Transplantation|August 6, 2003
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)A R Zander, N Kröger, M Schleuning, et al.
Bone Marrow Transplantation|February 9, 2016
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomasF Heinzelmann, W Bethge, D W Beelen, et al.
Bone Marrow Transplantation|June 2, 2016
Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?M C Oliveira, M Labopin, J Henes, et al.
ESMO Open|September 6, 2024
High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMTS Secondino, M Badoglio, G Rosti, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationS K Metzelder, T Schroeder, M Lübbert, et al.
Leukemia|June 1, 2017
High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study groupB Kasenda, G Ihorst, R Schroers, et al.
Bone Marrow Transplantation|December 1, 2015
Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working PartyS P Robinson, A Boumendil, H Finel, et al.
Bone Marrow Transplantation|November 2, 2004
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosisR Saccardi, A Tyndall, G Coghlan, et al.
Pageof 27